Thank you for your interest in this this survey to provide your perspectives on the impact of ALS.

ALS Canada is conducting this survey to gather information from people living with ALS and their caregivers about the impact of the disease, experiences with current treatments, and experiences with a specific new treatment, Radicava (edaravone; also called Radicut).

This survey is open to:
  • People living with ALS
  • Caregivers and family members for someone living with ALS
  • Caregivers and family members who have lost someone to ALS

You do not need to have specific experience with Radicava (edaravone) to participate. The survey will be open from June 11 to June 24, 2018.

The information you provide will help drug review decision-makers understand the impact of ALS when reviewing Radicava (edaravone). These reviews are important as governments will rely on them to decide whether or not to fund Radicava (edaravone), provided it is approved by Health Canada. ALS Canada wants to ensure that the stories and views of patients living with ALS are taken into account in these drug evaluations.

 
ABOUT RADICAVA (EDARAVONE)

Radicava is currently being reviewed in Canada by Health Canada and has not yet been approved. If you do not have experience with Radicava (edaravone), this survey will ask you about your expectations for this drug. For more information about Radicava, see MT Pharma's US website: www.radicava.com. For more information on the process for patients to access a new drug in Canada, see How new drugs become approved and available to Canadians on the ALS Canada Blog.


PRIVACY INFORMATION

By completing this survey, you consent to allowing ALS Canada and the ALS Societies across Canada to use this information for the CADTH patient input submission and for other advocacy initiatives. For the CADTH patient input submission, your health information and expressed opinions will be reviewed and summarized. Your name will not be associated with the information presented or published in any way. Any information that you provide that can identify you will remain confidential.

Please be aware that the CADTH patient input submission is publicly posted and shared with the individual provincial/territorial bodies who negotiate reimbursements costs with the manufacturer.

If you have read and consented to the use of your information as described above, please complete this survey no later than June 22, 2018. Any response submitted later than this date may not be included as part of ALS patient input submissions.

Thank you in advance for contributing. If you have any questions, please contact Lauren Poplak at ALS Canada (lpoplak@als.ca or 416-497-2267 ext. 213).

T